Molinoff P B
Drugs. 1984;28 Suppl 2:1-15. doi: 10.2165/00003495-198400282-00002.
The effects of catecholamines in the central and peripheral nervous systems appear to be mediated through interactions with 2 major classes of receptor: alpha-adrenoceptors and beta-adrenoceptors. Subtypes of both alpha- and beta-adrenoceptors exist. In the periphery, alpha 1-receptors are located postsynaptically, mediating the excitatory effects of catecholamines at alpha-receptors. alpha 2-Adrenoceptors, on the other hand, are autoreceptors involved in the regulation of noradrenaline (norepinephrine) release. In the central nervous system, both alpha 1- and alpha 2-receptors exist on postsynaptic cells; there are also 2 principal subtypes of beta-adrenoceptors. beta 1-Receptors have a high affinity for both noradrenaline and adrenaline (epinephrine) and are found in the heart, brain, and adipose tissue. beta 2-Receptors have a low affinity for noradrenaline and are involved in mediation of relaxation of vascular and other smooth muscles and in many of the metabolic effects of catecholamines. A variety of effector systems have been implicated in the actions of catecholamines. Most, though not all, of the effects of catecholamines at beta-receptors are mediated through activation of adenyl cyclase and increases in cyclic AMP accumulation. The effects of catecholamines at alpha-receptors generally involve other second messenger systems. Thus, in at least some systems, stimulation of alpha 1-adrenoceptors mediates increases in phosphoinositide breakdown, while alpha 2-adrenoceptors appear to act through inhibition of adenyl cyclase activity. The pharmacological effects of alpha- and beta-adrenoceptors were initially characterised by measuring responses observed in intact preparations. The advent of the use of radioligand binding techniques has allowed direct approaches to the characterisation of receptor properties. The use of radioligands makes it possible to determine the affinities of receptors for specific ligands, and it is possible to determine the density of receptors in a tissue. Finally, in vitro assays serve as a means through which receptors can be followed during solubilisation, isolation, and reconstitution. Several ligands are now available for the study of alpha- and beta-adrenoceptors. In general, relatively selective radioligands are available for the study of alpha-receptors. Thus, 3H-WB 4101 and 3H-prazosin are selective ligands for alpha 1-receptors; the ligand 125I-IBE 2254 also shows high selectivity for alpha 1-receptors. 3H-Yohimbine and 3H-rauwolscine are selective antagonists for the labelling of alpha 2-receptors and 3H-clonidine is a selective agonist used for studying alpha 2-receptors.(ABSTRACT TRUNCATED AT 400 WORDS)
α-肾上腺素能受体和β-肾上腺素能受体。α-和β-肾上腺素能受体均存在亚型。在外周,α1受体位于突触后,介导儿茶酚胺在α受体处的兴奋作用。另一方面,α2肾上腺素能受体是参与去甲肾上腺素释放调节的自身受体。在中枢神经系统中,突触后细胞上同时存在α1和α2受体;β-肾上腺素能受体也有两种主要亚型。β1受体对去甲肾上腺素和肾上腺素(肾上腺素)都有高亲和力,见于心脏、脑和脂肪组织。β2受体对去甲肾上腺素亲和力低,参与介导血管和其他平滑肌的舒张以及儿茶酚胺的许多代谢作用。多种效应系统与儿茶酚胺的作用有关。儿茶酚胺在β受体处的大多数(尽管不是全部)效应是通过激活腺苷酸环化酶和增加环磷酸腺苷积累来介导的。儿茶酚胺在α受体处的效应通常涉及其他第二信使系统。因此,在至少一些系统中,刺激α1肾上腺素能受体介导磷酸肌醇分解增加,而α2肾上腺素能受体似乎通过抑制腺苷酸环化酶活性起作用。α-和β-肾上腺素能受体的药理作用最初是通过测量在完整制剂中观察到的反应来表征的。放射性配体结合技术的出现使得直接表征受体特性成为可能。使用放射性配体可以确定受体对特定配体的亲和力,也可以确定组织中受体的密度。最后,体外测定是在受体溶解、分离和重组过程中跟踪受体的一种手段。现在有几种配体可用于研究α-和β-肾上腺素能受体。一般来说,有相对选择性的放射性配体可用于研究α受体。因此,3H-WB 4101和3H-哌唑嗪是α1受体的选择性配体;配体125I-IBE 2254对α1受体也表现出高选择性。3H-育亨宾和3H-萝芙木碱是用于标记α2受体的选择性拮抗剂,3H-可乐定是用于研究α2受体的选择性激动剂。(摘要截短于400字)